Koselugo (selumetinib) is a small molecule pharmaceutical. Selumetinib was first approved as Koselugo on 2020-04-10. It is used to treat neurofibromatosis 1 in the USA. The pharmaceutical is active against dual specificity mitogen-activated protein kinase kinase 1 and dual specificity mitogen-activated protein kinase kinase 2. In addition, it is known to target serine/threonine-protein kinase B-raf. Koselugo's patents are valid until 2026-12-12 (FDA).
|Drug Class||Tyrosine kinase inhibitors: mitogen-activated protein (MAP) kinase inhibitors|